Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T-cell therapy in HIV-1 infection
NCT04863066Phase 1Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- May 2021
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-T cells-Beijing 302 Hospital-HIV-1 infection in human immunodeficiency virus type 1 infection (HIV-1), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Safety of CAR-T-cell treatment at 3 months. Status: unknown.
02
Drugs
CAR-T cells-Beijing 302 Hospital-HIV-1 infection
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04863066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863066.